Peptide receptor radionuclide therapy for neuroendocrine Tumors in Germany: First results of a multi-institutional cancer registry

Dieter Hörsch, Samer Ezziddin, Alexander Haug, Klaus Friedrich Gratz, Simone Dunkelmann, Bernd Joachim Krause, Carl Schümichen, Frank M. Bengel, Wolfram H. Knapp, Peter Bartenstein, Hans Jürgen Biersack, Ursula Plöckinger, Sabine Schwartz-Fuchs, R. P. Baum

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Peptide receptor radionuclide therapy is an effective treatment option for patients with well-differentiated somatostatin receptor-expressing neuroendocrine tumors. However, published data result mainly from retrospective monocentric studies. We initiated a multi-institutional, prospective, board-reviewed registry for patients treated with peptide receptor radionuclide therapy in Germany in 2009. In five centers, 297 patients were registered. Primary tumors were mainly derived from pancreas (117/297) and small intestine (80/297), whereas 56 were of unknown primary. Most tumors were well differentiated with median Ki67 proliferation rate of 5% (range 0.9-70%). Peptide receptor radionuclide therapy was performed using mainly yttrium-90 and/or lutetium-177 as radionuclides in 1-8 cycles. Mean overall survival was estimated at 213 months with follow-up between 1 and 230 months after initial diagnosis, and 87 months with follow-up between 1 and 92 months after start of peptide receptor radionuclide therapy. Median overall survival was not yet reached. Subgroup analysis demonstrated that best results were obtained in neuroendocrine tumors with proliferation rate below 20%. Our results indicate that peptide receptor radionuclide therapy is an effective treatment for well- and moderately differentiated neuroendocrine tumors irrespective of previous therapies and should be regarded as one of the primary treatment options for patients with somatostatin receptor-expressing neuroendocrine tumors.

Original languageEnglish (US)
Title of host publicationTheranostics, Gallium-68, and Other Radionuclides
Subtitle of host publicationA Pathway to Personalized Diagnosis and Treatment
Pages457-465
Number of pages9
DOIs
StatePublished - Jan 1 2013

Publication series

NameRecent Results in Cancer Research
Volume194
ISSN (Print)0080-0015

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Peptide receptor radionuclide therapy for neuroendocrine Tumors in Germany: First results of a multi-institutional cancer registry'. Together they form a unique fingerprint.

Cite this